Vimarsana
Biggest News Aggregation in the World

Viking Global News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Viking Global. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Viking Global Today - Breaking & Trending Today

Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) - Vimarsana News

Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV)

We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss why institutional investors are bullish on Roivant Sciences Ltd. (NASDAQ:ROIV). Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due to its need. According to a World […]

Source: yahoo.com
HI-Bio Announces Positive Results From Phase 2 Study Of Felzartamab For Late Antibody-Mediated Rejection In Kidney Transplant Recipients - Vimarsana News

HI-Bio Announces Positive Results From Phase 2 Study Of Felzartamab For Late Antibody-Mediated Rejection In Kidney Transplant Recipients

82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n

Source: menafn.com
10 Unstoppable Growth Stocks To Buy - Insider Monkey - Vimarsana News

10 Unstoppable Growth Stocks To Buy - Insider Monkey

Growth stocks have been outperforming value stocks for quite a while.

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences - Vimarsana News

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational...

Biogen Inc.: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences - Vimarsana News

Biogen Inc.: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational